InteRNA Technologies

InteRNA Technologies last week announced that it is collaborating with the University of Bonn and Belgian biopharmaceutical firm UCB to identify and study microRNAs as therapeutic targets for neurodegenerative diseases.

NEW YORK (GenomeWeb News) – The European Union has provided €11.5 million ($15.4 million) to fund an international research consortium that will seek to investigate the roles microRNAs play in epilepsy and how they may be used to develop new diagnostics and treatments for the disease.

Dutch microRNA drug developer InteRNA Technologies this month announced that it has received a notice of allowance from the US Patent and Trademark Office for a patent application covering a number of novel microRNA sequences, including one that forms the basis of the company's l

Under the deal, InteRNA’s lentiviral-based miRNA over-expression library will be used in “multi-parametric, high-throughput functional screening assays” to identify the role of individual miRNAs in various cancer pathways. The company hopes to discover novel miRNAs as therapeutic targets.

The arrangement will take advantage of InteRNA's proprietary lentiviral-based miRNA over-expression library, according to the partners.

In doing so, SIROCCO is meeting its goal of making its discoveries and technologies freely accessible to the research community.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Futurism writes that gene doping could be the next generation of cheating in sports.